These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28254605)

  • 1. Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.
    Stainton SM; Thabit AK; Kuti JL; Aslanzadeh J; Nicolau DP
    Clin Microbiol Infect; 2017 Aug; 23(8):581-582. PubMed ID: 28254605
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Stainton SM; Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia.
    Marimuthu K; Ng TM; Teng C; Lim TP; Koh TH; Tan TY; Krishnan PU; Lye D
    J Infect; 2013 Mar; 66(3):294-6. PubMed ID: 23201151
    [No Abstract]   [Full Text] [Related]  

  • 8. [Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae].
    Grados M; Fernández S; Lara N; Alós JI
    Rev Esp Quimioter; 2017 Aug; 30(4):299-300. PubMed ID: 28541011
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
    Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
    Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
    Monogue ML; Tanner LK; Brecher SM; Aslanzadeh J; Nicolau DP
    Infect Control Hosp Epidemiol; 2017 Mar; 38(3):379-380. PubMed ID: 28069100
    [No Abstract]   [Full Text] [Related]  

  • 11. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
    Gavin PJ; Suseno MT; Thomson RB; Gaydos JM; Pierson CL; Halstead DC; Aslanzadeh J; Brecher S; Rotstein C; Brossette SE; Peterson LR
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2244-7. PubMed ID: 16723596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.
    Hyle EP; Ferraro MJ; Silver M; Lee H; Hooper DC
    Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1242-9. PubMed ID: 21029005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
    Delgado-Valverde M; Torres E; Valiente-Mendez A; Almirante B; Gómez-Zorrilla S; Borrell N; Corzo JE; Gurgui M; Almela M; García-Álvarez L; Fontecoba-Sánchez MC; Martínez-Martínez L; Cantón R; Praena J; Causse M; Gutiérrez-Gutiérrez B; Roberts JA; Farkas A; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2016 Feb; 71(2):521-30. PubMed ID: 26538507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
    Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
    [No Abstract]   [Full Text] [Related]  

  • 20. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.